News

Currie Medical to expand in Norfolk

Currie Medical, a medical device manufacturer, plans to invest $1.22 million to expand its operations in Norfolk, creating an estimated 60 jobs.

Based in Franklin, Tennessee, Currie Medical will lease a 30,000-square-foot building at 3701 E. Virginia Beach Blvd. in Norfolk, where it will house its medical device reprocessing operation and distribution center. Currie has 15 employees in Norfolk and employs about 45 people total between Virginia and Tennessee, according to co-owner Carter Smith. The new facility is expected to be in full operation and fully staffed in the first quarter of 2025, he added.

“Currie Medical is excited to expand our operations into the vibrant business community of Norfolk,” Smith and co-owner Owen Griffin said in a statement. “This region offers us a skilled workforce, strong infrastructure and a supportive environment that fosters growth and innovation in the medical technology sector. With this investment, we are committed to bringing new job opportunities to the area and continuing to develop new solutions in medical device reprocessing. We look forward to contributing to the advancement of health care with our growing Norfolk-based team.”

The Virginia Economic Development Partnership worked with the City of Norfolk and the Hampton Roads Economic Development Alliance to secure the project, and the Virginia Jobs Investment Program will assist Currie Medical with consultation and funding for recruitment and training activities. The company is also eligible for state benefits through the Port of Virginia Economic and Infrastructure Development Zone Grant Program.

“Currie Medical’s expansion in Norfolk highlights Virginia’s growing prowess in specialized manufacturing,” Gov. Glenn Youngkin said in a statement. “This project not only adds to our skilled workforce but also strengthens our reputation as a hub for innovative medical technology solutions. We are proud to have them in the commonwealth for years to come.”

Read more here.

Recent News

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients